Introduction: Magnetic resonance-guided focused ultrasound (MRgFUS) is well-established for the treatment of essential tremor and is emerging as a promising non-incisional treatment for Parkinson's disease (PD). However, its safety in this context is not well established.
Methods: We performed a systematic review and meta-analysis to evaluate the incidence of adverse events among patients with medication-refractory PD treated with MRgFUS. PubMed, Embase, Scopus, and Cochrane databases were searched from inception until December 2023. Included studies were peer-reviewed randomized controlled trials (RCTs) comparing MRgFUS to sham-procedures among patients with medication-refractory PD.
Results: Three RCTs comprising 161 patients (MRgFUS n = 115) were included. Dizziness was the most reported adverse event associated with MRgFUS (odds ratio [OR] 4.25; 95 % confidence interval [CI] 1.23-14.64; p = 0.02; I = 0 %). Pin-site complications (OR 0.52; 95 % CI 0.23-1.20; I = 0 %) and headache (OR 0.88; 95 % CI 0.19-4.16; I = 48 %) were also notable. Ablation-related adverse events included gait disturbances (OR 4.53; 95 % CI 0.79-26.07; p = 0.09; I = 0 %) and facial disturbances (OR 2.93; 95 % CI 0.49-17.51). No significant between-group differences were observed for life-threatening events (OR 1.76, 95 % CI 0.55-5.65; p = 0.35; I = 0 %).
Conclusion: MRgFUS demonstrated a reasonable safety profile for the treatment of patients with medication-refractory PD. This promising safety profile, combined with its non-incisional nature, supports its potential as a valuable tool for managing refractory PD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jocn.2025.111159 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pulmonary Artery Denervation for Medication Refractory Pulmonary Hypertension (PARPH Study) - Study Protocol for a Prospective, Open-Label, Single-Arm Clinical Trial.
Circ Rep
March 2025
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center Osaka Japan.
Background: Despite the development of effective pulmonary vasodilators, the prognosis for patients with pulmonary hypertension (PH) remains poor, particularly in medication-refractory patients. Catheter-based pulmonary artery denervation (PADN) is an emerging therapeutic strategy targeting the sympathetic nervous system in various types of PH. However, data on its safety and efficacy in refractory patients with PH who truly require non-pharmacotherapy are lacking.
View Article and Find Full Text PDFSafety of Focused Ultrasound Ablation in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials.
J Clin Neurosci
March 2025
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Introduction: Magnetic resonance-guided focused ultrasound (MRgFUS) is well-established for the treatment of essential tremor and is emerging as a promising non-incisional treatment for Parkinson's disease (PD). However, its safety in this context is not well established.
Methods: We performed a systematic review and meta-analysis to evaluate the incidence of adverse events among patients with medication-refractory PD treated with MRgFUS.
Performance of Closed-Loop DBS During Sleep in Patients with Essential Tremor.
Annu Int Conf IEEE Eng Med Biol Soc
July 2024
Deep Brain Stimulation (DBS) has emerged as an effective therapy for people suffering from medication refractory essential tremor (ET). Significant tremor suppression for patients can be achieved by targeting and stimulating the thalamic ventral intermediate nucleus (VIM). In clinical practice, DBS is delivered continuously, resulting in stimulation when not needed, particularly during sleep when tremor is not experienced.
View Article and Find Full Text PDFComparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication-Refractory Parkinson's Disease Tremor.
Mov Disord
March 2025
Centro Integral de Neurociencias AC (CINAC), HM Universitario Puerta del Sur, Madrid, Spain.
Background: Unilateral focused ultrasound ventral intermediate thalamotomy (Vim-FUS) is effective in treating Parkinson's disease (PD) tremor. Ultrasound ablation of the subthalamic nucleus (STN-FUS) has demonstrated efficacy in improving all cardinal motor features of PD, including tremor.
Objective: To compare the efficacy in parkinsonian tremor control between Vim-FUS and STN-FUS.
Focused Ultrasound as Rescue Treatment of Essential Tremor After Deep Brain Stimulation: 2 Case Reports.
Neurosurg Pract
September 2024
Movement Disorders Unit, Neurology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
Background And Importance: Approximately 25% to 55% of patients with essential tremor will eventually develop medication-refractory tremor. Currently, the standard surgical treatment for this condition is deep brain stimulation (DBS) of the ventralis intermedius nucleus of the thalamus and, more recently, the posterior subthalamic area. However, MRI-guided focused ultrasound (FUS) thalamotomy has shown promising results in improving tremor in patients with refractory essential tremor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!